| ID | 10002 |
| Vaccine Name | CoronaVac |
| Disease Name | COVID-19 |
| Disease Classification | Respiratory |
| Virus Name | SARS-CoV-2 virus |
| Nucleic Acid Content | positive-sense, single-stranded RNA |
| Vaccine Type | Inactivated |
| Vaccine Status | Approved |
| Manufacturer | Sinovac Biotech Ltd. |
| Year of Manufacturing | 2021 |
| Manufacturing Country | China |
| Age | 18 - 59 years |
| Dosage | 2 doses 28 days apart |
| Administration Route | Intramuscular |
| Adjuvant | NA |
| Target Strain | Antigenic strain of H1N1, H3N2, BV and BY |
| Description | NA |
| Approving Organisation | NA |
| Collaborating Organisation | NA |
| Other Countries | NA |
| Trade Name | PiCoVacc, Inactivated SARS-CoV-2 vaccine (Vero cell) |
| PMID | NA |
| Clinical Trial ID | NCT04801888 |
| Reference Link | https://clinicaltrials.gov/show/NCT04801888 |
| Additional Links | https://cdn.who.int/media/docs/default-source/immunization/sage/2021/april/4_sage29apr2021_sinovac.pdf
|